Tarulli Gerard A, Butler Lisa M, Tilley Wayne D, Hickey Theresa E
Dame Roma Mitchell Cancer Research Laboratories (DRMCRL)Faculty of Health Sciences, School of Medicine, The University of Adelaide, Adelaide, South Australia 5005, Australia
Dame Roma Mitchell Cancer Research Laboratories (DRMCRL)Faculty of Health Sciences, School of Medicine, The University of Adelaide, Adelaide, South Australia 5005, Australia.
Endocr Relat Cancer. 2014 Aug;21(4):T183-202. doi: 10.1530/ERC-14-0248. Epub 2014 Jul 7.
While it has been known for decades that androgen hormones influence normal breast development and breast carcinogenesis, the underlying mechanisms have only been recently elucidated. To date, most studies have focused on androgen action in breast cancer cell lines, yet these studies represent artificial systems that often do not faithfully replicate/recapitulate the cellular, molecular and hormonal environments of breast tumours in vivo. It is critical to have a better understanding of how androgens act in the normal mammary gland as well as in in vivo systems that maintain a relevant tumour microenvironment to gain insights into the role of androgens in the modulation of breast cancer development. This in turn will facilitate application of androgen-modulation therapy in breast cancer. This is particularly relevant as current clinical trials focus on inhibiting androgen action as breast cancer therapy but, depending on the steroid receptor profile of the tumour, certain individuals may be better served by selectively stimulating androgen action. Androgen receptor (AR) protein is primarily expressed by the hormone-sensing compartment of normal breast epithelium, commonly referred to as oestrogen receptor alpha (ERa (ESR1))-positive breast epithelial cells, which also express progesterone receptors (PRs) and prolactin receptors and exert powerful developmental influences on adjacent breast epithelial cells. Recent lineage-tracing studies, particularly those focussed on NOTCH signalling, and genetic analysis of cancer risk in the normal breast highlight how signalling via the hormone-sensing compartment can influence normal breast development and breast cancer susceptibility. This provides an impetus to focus on the relationship between androgens, AR and NOTCH signalling and the crosstalk between ERa and PR signalling in the hormone-sensing component of breast epithelium in order to unravel the mechanisms behind the ability of androgens to modulate breast cancer initiation and growth.
几十年来,人们已经知道雄激素会影响正常乳腺发育和乳腺癌发生,但其中的潜在机制直到最近才得以阐明。迄今为止,大多数研究都集中在雄激素在乳腺癌细胞系中的作用,然而这些研究代表的是人工系统,往往无法如实地复制/重现体内乳腺肿瘤的细胞、分子和激素环境。更好地了解雄激素在正常乳腺以及维持相关肿瘤微环境的体内系统中的作用机制,对于深入了解雄激素在调节乳腺癌发展中的作用至关重要。这反过来将促进雄激素调节疗法在乳腺癌中的应用。这一点尤为重要,因为目前的临床试验聚焦于抑制雄激素作用作为乳腺癌治疗手段,但根据肿瘤的类固醇受体谱,某些个体可能通过选择性刺激雄激素作用而得到更好的治疗效果。雄激素受体(AR)蛋白主要由正常乳腺上皮的激素感知部分表达,通常称为雌激素受体α(ERα(ESR1))阳性乳腺上皮细胞,这些细胞也表达孕激素受体(PRs)和催乳素受体,并对相邻的乳腺上皮细胞发挥强大的发育影响。最近的谱系追踪研究,特别是那些聚焦于NOTCH信号通路的研究,以及对正常乳腺癌症风险的基因分析,突出了通过激素感知部分的信号传导如何影响正常乳腺发育和乳腺癌易感性。这促使人们关注雄激素、AR和NOTCH信号通路之间的关系,以及乳腺上皮激素感知成分中ERα和PR信号通路之间的相互作用,以便揭示雄激素调节乳腺癌起始和生长能力背后的机制。